Goldman Sachs
TBPH icon

Goldman Sachs’s Theravance Biopharma TBPH Stock Holding History

Goldman Sachs’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.75M Buy
416,143
+125,279
+43% +$2.22M ﹤0.01% 3408
2025
Q4 		$5.44M Buy
290,864
+32,216
+12% +$534K ﹤0.01% 3671
2025
Q3 		$3.78M Buy
258,648
+59,262
+30% +$749K ﹤0.01% 3904
2025
Q2 		$2.2M Sell
199,386
-11,150
-5% -$108K ﹤0.01% 4103
2025
Q1 		$1.88M Sell
210,536
-14,567
-6% -$136K ﹤0.01% 4207
2024
Q4 		$2.12M Sell
225,103
-64,686
-22% -$589K ﹤0.01% 4224
2024
Q3 		$2.34M Sell
289,789
-43,762
-13% -$379K ﹤0.01% 4015
2024
Q2 		$2.83M Buy
333,551
+110,801
+50% +$1M ﹤0.01% 3657
2024
Q1 		$2M Sell
222,750
-63,541
-22% -$589K ﹤0.01% 3866
2023
Q4 		$3.22M Buy
286,291
+16,506
+6% +$166K ﹤0.01% 3548
2023
Q3 		$2.33M Sell
269,785
-70,814
-21% -$684K ﹤0.01% 3652
2023
Q2 		$3.53M Buy
340,599
+4,172
+1% +$46.1K ﹤0.01% 3410
2023
Q1 		$3.65M Sell
336,427
-9,556
-3% -$101K ﹤0.01% 3353
2022
Q4 		$3.88M Sell
345,983
-276,876
-44% -$2.91M ﹤0.01% 3400
2022
Q3 		$6.32M Buy
622,859
+39,830
+7% +$373K ﹤0.01% 2931
2022
Q2 		$5.28M Sell
583,029
-393,344
-40% -$3.62M ﹤0.01% 3082
2022
Q1 		$9.34M Buy
976,373
+632,582
+184% +$6.2M ﹤0.01% 2762
2021
Q4 		$3.8M Buy
343,791
+39,534
+13% +$345K ﹤0.01% 3687
2021
Q3 		$2.25M Buy
304,257
+16,498
+6% +$185K ﹤0.01% 4086
2021
Q2 		$4.18M Buy
287,759
+6,639
+2% +$125K ﹤0.01% 3499
2021
Q1 		$5.74M Sell
281,120
-68,389
-20% -$1.3M ﹤0.01% 3010
2020
Q4 		$6.21M Buy
349,509
+34,344
+11% +$617K ﹤0.01% 2852
2020
Q3 		$4.66M Sell
315,165
-18,780
-6% -$352K ﹤0.01% 2960
2020
Q2 		$7.01M Buy
333,945
+163,735
+96% +$4.21M ﹤0.01% 2537
2020
Q1 		$3.93M Buy
170,210
+53,562
+46% +$1.34M ﹤0.01% 2826
2019
Q4 		$3.02M Sell
116,648
-1,681
-1% -$32.7K ﹤0.01% 3349
2019
Q3 		$2.31M Sell
118,329
-126,889
-52% -$2.56M ﹤0.01% 3438
2019
Q2 		$4M Sell
245,218
-20,671
-8% -$419K ﹤0.01% 3003
2019
Q1 		$6.03M Buy
265,889
+31,071
+13% +$788K ﹤0.01% 2822
2018
Q4 		$6.01M Buy
234,818
+15,475
+7% +$418K ﹤0.01% 2725
2018
Q3 		$7.17M Sell
219,343
-3,182
-1% -$86.7K ﹤0.01% 2709
2018
Q2 		$5.05M Sell
222,525
-247,692
-53% -$5.88M ﹤0.01% 2957
2018
Q1 		$11.4M Buy
470,217
+272,599
+138% +$7.49M ﹤0.01% 2229
2017
Q4 		$5.51M Sell
197,618
-59,190
-23% -$1.75M ﹤0.01% 2937
2017
Q3 		$8.79M Buy
256,808
+17,632
+7% +$577K ﹤0.01% 2668
2017
Q2 		$9.53M Sell
239,176
-16,934
-7% -$651K ﹤0.01% 2548
2017
Q1 		$9.43M Buy
256,110
+198,062
+341% +$6.33M ﹤0.01% 2456
2016
Q4 		$1.85M Buy
58,048
+31,736
+121% +$984K ﹤0.01% 3925
2016
Q3 		$954K Buy
26,312
+10,430
+66% +$290K ﹤0.01% 4440
2016
Q2 		$360K Buy
15,882
+1,335
+9% +$28.8K ﹤0.01% 5185
2016
Q1 		$273K Sell
14,547
-4,288
-23% -$70.2K ﹤0.01% 5352
2015
Q4 		$309K Buy
18,835
+3,805
+25% +$60.4K ﹤0.01% 5329
2015
Q3 		$165K Buy
+15,030
New +$191K ﹤0.01% 6136
2014
Q3 		– Sell
-7,346
Closed -$234K – 7255
2014
Q2 		$234K Buy
+7,346
New +$221K ﹤0.01% 6073

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's TBPH Position: Q1 2026 in Review

Goldman Sachs increased its Theravance Biopharma (TBPH) stake by 43% in Q1 2026, buying an estimated $2.22M and bringing the position to 416,143 shares worth $6.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

Goldman Sachs first reported a position in TBPH in Q2 2014 and has held it in 44 quarters since. The position peaked at $11.4M in Q1 2018. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Goldman Sachs held 416,143 shares of Theravance Biopharma worth $6.75M as of Q1 2026.
  • Goldman Sachs bought 125,279 Theravance Biopharma shares in Q1 2026, an estimated $2.22M.
  • Theravance Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3408 holding.
  • Goldman Sachs first reported a position in Theravance Biopharma in Q2 2014 and has held it in 44 quarters since.
  • Goldman Sachs's Theravance Biopharma position peaked at $11.4M in Q1 2018.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.